Axios Re:Cap

The push to legalize psychedelics for mental health

Clinical research treating mental illness with psychedelics has been ongoing for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.
Dan digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Each weekday afternoon, Axios unpacks the biggest story of the day and why it matters. We'll take you inside the accelerating forces, technologies and trends that are remaking your world and work. About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app. 

Axios Re:Cap is on hiatus until October 2021.